<DOC>
	<DOCNO>NCT00055185</DOCNO>
	<brief_summary>The purpose study determine adverse effect PRO 542 administration determine anti-HIV effect PRO 542 patient .</brief_summary>
	<brief_title>Safety Efficacy PRO 542 Treatment HIV-Infected Patients</brief_title>
	<detailed_description>A 2 arm study involve series 3 triweekly dos PRO 542 . One arm involve patient stable dose anti-retroviral therapy arm consist patient receive anti-retroviral therapy . Three patient enrol arm follow safety evaluation . Following safety evaluation , 3 patient may enrol arm . After first 12 patient , additional 12 patient may enrol pending safety data .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>CD4 Immunoadhesins</mesh_term>
	<criteria>Confirmed diagnosis HIV Patients must stable dose acceptable antiHIV therapy receive antiHIV therapy least four ( 4 ) week prior start study HIV1 determination RNAPCR great equal 100,000 copies/ml CD4 count &gt; 50/cubic mm screen Patients previously receive PRO 542 Patients active , significant infection ( HIV ) control antibiotic Pregnant lactate woman Patients estimated life expectancy &lt; 3 month Patients currently receive steroid immunosuppressive therapy immunoglobulin therapy except topical inhaled steroid Patients know allergy hypersensitivity PRO 542 immunoglobulin preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>